Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
0.0×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0.0×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
0.0×
Biohaven logo
BiohavenBHVN
0.6×+0.5×
Septerna, Inc. logo
Septerna, Inc.SEPN
0.0×

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s debt-to-assets?
Rapport Therapeutics, Inc. (RAPP) reported debt-to-assets of 0× in Q1 2026.
How has Rapport Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Rapport Therapeutics, Inc.'s debt-to-assets decreased by 16.5% year-over-year, from 0× to 0×.
What is the long-term trend for Rapport Therapeutics, Inc.'s debt-to-assets?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s debt-to-assets has grown at a 27.4% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.